Key takeaways: CBT-004 demonstrated rapid onset of improvement in conjunctival hyperemia. Cloudbreak Pharma is advancing CBT-004 to phase 3 development. Cloudbreak Pharma reported positive topline ...

Christopher J. Rapuano, MD Disclosures March 08, 2012 Squamous Carcinoma and Dysplasia of the Conjunctiva and Cornea: An Analysis of 101 Cases Yousef YA, Finger PT Ophthalmology. 2012;119;223-240 ...

Novel preservative-free CBT-004 eye drop formulation demonstrates statistically significant improvements in conjunctival hyperemia and patient-reported symptoms with excellent safety profile ...

Novel preservative-free CBT-004 eye drop formulation demonstrates statistically significant improvements in conjunctival hyperemia and patient-reported symptoms with excellent safety profile ...

Conjunctival melanosis can increase with age, and is not shown to often progress to melanoma. But patients can still develop melanoma, so medical professionals recommend annual screenings.